News

Novavax (NASDAQ: NVAX) shares declined 6% following a report from the Wall Street Journal that said federal regulators are ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...